论文部分内容阅读
目的:本文研究主要就子宫腺肌病患者采用超小剂量米非司酮进行治疗的相关情况展开分析讨论,以此来为此类患者的临床治疗提供参考。方法:选择我院2009年4月—2013年4月所收治的53例子宫腺肌病患者作为研究对象,利用随机数字法将其分成观察组与对照组,观察组的26例患者给予6.25mg/d米非司酮口服治疗,对照组的27例患者给予避孕药口服治疗,所有患者均经过6个月的治疗,比较两组患者的治疗效果、不良反应发生率、以及内分泌功能变化情况。结果:观察组患者的治疗总有效率为96.15%,对照组患者的治疗总有效率为70.37%,两组患者的治疗总有效率存在明显差异,具有统计学意义,P<0.05;观察组不良反应发生率为19.23%;对照组为51.85%,两组患者的不良反应发生率存在明显差异,具有统计学意义,P<0.05。结论:在对子宫腺肌病患者进行临床治疗时,采用超小剂量米非司酮来对患者进行治疗,其具有对内分泌影响小、副作用小、有效、安全等优点,因此,在对子宫腺肌病患者进行临床治疗时,可以用超小剂量米非司酮治疗的方式大力推广并普及实施。
OBJECTIVE: In this paper, we mainly analyze and discuss the related situation of using ultra-low dose mifepristone for treatment of patients with adenomyosis so as to provide reference for the clinical treatment of such patients. Methods: Fifty-three patients with adenomyosis admitted in our hospital from April 2009 to April 2013 were selected as study subjects and divided into observation group and control group using random number method. 26 patients in observation group were given 6.25 mg / d mifepristone oral treatment, control group of 27 patients given oral contraceptives, all patients after 6 months of treatment, the two groups were compared the treatment effect, the incidence of adverse reactions, and changes in endocrine function. Results: The total effective rate was 96.15% in the observation group and 70.37% in the control group. There was significant difference between the two groups in the total effective rate of treatment, with statistical significance (P <0.05). In the observation group, the total effective rate was 96.15% The incidence of the reaction was 19.23%; the control group was 51.85%. There was a significant difference in the incidence of adverse reactions between the two groups, with statistical significance (P <0.05). Conclusion: In the clinical treatment of patients with adenomyosis, the use of ultra-low dose of mifepristone in patients with treatment, which has little effect on endocrine, side effects, effective, safe, and so on, therefore, in the uterus gland Myopathy patients for clinical treatment, you can use ultra-low dose mifepristone treatment to promote and popularize the way.